8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-methanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-methanol
• 英文别名: [8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepin-2-yl]methanol
• 化学式: C₁₈H₁₃ClFN₃O
• 分子量: 341.772
• InChiKey: CKUKBHJJPKUGQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  50.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-methanol 在 三溴化磷 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 0.5h， 生成 {[12-chloro-9-(2-fluorophenyl)-2,5,8-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(10),3,5,8,11,13-hexaen-4-yl]methyl}trimethylazanium chloride
  参考文献：
  名称：

  [EN] PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM
  [FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DE GABA À RESTRICTION PÉRIPHÉRIQUE POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE ET AUTRES AFFECTIONS DU SYSTÈME NERVEUX PÉRIPHÉRIQUE

  摘要：

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.

  公开号：

  WO2024030543A2
• 作为产物：
  描述：

  7-chloro-2-(3,3-diethoxy-1-hydroxy-2-propylamino)-5-(2-fluorophenyl)-3H-1,4-benzodiazepine 在 sodium hydroxide 、 乙醇 、 氯仿 、 氯化钠 、 Sodium sulfate-III 、 residue 、 silica gel 、 desired product 、 diethyl ether ethyl acetate 作用下， 以 溶剂黄146 为溶剂， 反应 7.0h， 以were obtained 11.6 g of 8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-methanol of m.p. 196-199.5° C的产率得到8-chloro-6-(2-fluorophenyl)-4H-imidazo[1,2-a][1,4]benzodiazepine-2-methanol
  参考文献：
  名称：

  Hydroxymethylimidazodiazepines and their esters

  摘要：

  这项发明涉及一种通式为I的羟甲基咪唑二氮平及其酯类化合物。这些化合物可用作抗焦虑、抗惊厥、肌肉松弛和镇静催眠活性物质。

  公开号：

  US06174881B1

文献信息

• [DE] HYDROXYMETHYL-IMIDAZODIAZEPINE UND DEREN ESTER<br/>[EN] HYDROXYMETHYLIMIDAZODIAZEPINES AND THEIR ESTERS<br/>[FR] HYDROXYMETHYLIMIDAZODIAZEPINES ET LEURS ESTERS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：WO1996020941A1

  公开（公告）日：1996-07-11

  (DE) Die Erfindung betrifft Hydroxymethyl-imidazodiazepine und deren Ester der allgemeinen Formel (I). Diese Verbindungen können als anxiolytische und/oder antikonvulsive und/oder muskelrelaxierende und/oder sedativ-hypnotische Wirkstoffe angewendet werden, worin A zusammen mit den beiden mit $g(a) und $g(b) bezeichneten Kohlenstoffatomen einen der Reste (A1), (A2) oder (A3), R1 Wasserstoff oder nieder-Alkanoyl; R2 Phenyl, o-Halophenyl oder 2-Pyridyl; R3 Wasserstoff, nieder-Alkyl, Methylaminomethyl, Allylaminomethyl oder Diethylaminomethyl; R4 Halogen, CF3 oder Nitro; R5 Wasserstoff oder Halogen bedeuten.(EN) The invention pertains to hydroxymethylimidazodiazepines of general formula (I) and their esters. These compounds can be used as anxiolytic and/or anticonvulsive and/or muscle-relaxing and/or sedative hypnotic agents. In formula (I), A together with the two carbon atoms designated as $g(a) and $g(b) is one of the radicals (A1), (A2) or (A3); R1 is hydrogen or lower alkanoyl; R2 is phenyl, o-halophenyl or 2-pyridyl; R3 is hydrogen, lower alkyl, methylaminomethyl, allylaminomethyl or diethylaminomethyl; R4 is halogen, CF3 or nitro; R5 is hydrogen or halogen.(FR) L'invention concerne des hydroxyméthylimidazodiazépines de formule générale (I), ainsi que leurs esters. Ces composés peuvent être utilisés sous forme de principes actifs anxiolytiques et/ou anticonvulsifs et/ou myorelaxants et/ou sédatifs hypnotiques. Dans la formule (I), A représente, avec les deux atomes de carbone désignés par $g(a) et $g(b), un des radicaux (A1), (A2) ou (A3); R1 représente hydrogène ou alcanoyle inférieur; R2 représente phényle, o-halophényle ou 2-pyridyle; R3 représente hydrogène, alkyle inférieur, méthylaminométhyle, allylaminométhyle ou diéthylaminométhyle; R4 représente halogène, CF3 ou nitro; R5 représente hydrogène ou halogène.

  这项发明涉及一般公式(I)的羟甲基甲离子杂甲氧环胞嘧啶及其酯。这些化合物可以作为抗焦虑药、抗癫痫药、肌肉 relaxant 和莨菪 alkaloid 使用。在公式(I)中，A与两个标记为 $g(a) 和 $g(b) 的碳原子一起构成(A1)、(A2) 或 (A3)中的一个，R1是氢或低级的酸酐；R2是苯、o-卤苯或2-吡啶；R3是氢、低级烷基、甲基氨基甲基、 allyl氨基甲基或 diethyl氨基甲基；R4是卤素、CF3或硝基；R5是氢或卤素。
• HYDROXYMETHYL-IMIDAZODIAZEPINE UND DEREN ESTER
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0801651B1

  公开（公告）日：2001-07-11
• US6174881B1
  申请人：——

  公开号：US6174881B1

  公开（公告）日：2001-01-16
• Hydroxymethylimidazodiazepines and their esters
  申请人：Hoffman-La Roche Inc.

  公开号：US06174881B1

  公开（公告）日：2001-01-16

  The invention is concerned with hydroxymethyl-imidazodiazepines and their esters of general formula I. These compounds can be used as anxiolytic and/or anticonvulsant and/or muscle relaxant and/or sedative-hypnotic active substances.

  这项发明涉及羟甲基咪唑二氮杂环己酮及其一般式I的酯类化合物。这些化合物可用作抗焦虑、抗癫痫、肌肉松弛和催眠-催眠活性物质。
• [EN] PERIPHERALLY RESTRICTED GABA POSITIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME AND OTHER AILMENTS OF THE PERIPHERAL NERVOUS SYSTEM<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DE GABA À RESTRICTION PÉRIPHÉRIQUE POUR LE TRAITEMENT DU SYNDROME DU CÔLON IRRITABLE ET AUTRES AFFECTIONS DU SYSTÈME NERVEUX PÉRIPHÉRIQUE
  申请人：[en]THE JOHNS HOPKINS UNIVERSITY

  公开号：WO2024030543A2

  公开（公告）日：2024-02-08

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof, or an N-oxide thereof), which are positive allosteric modulators of one or more GABA-A receptors, e.g., which are peripherally restricted, positive allosteric modulators of one or more GABA-A receptors; e.g., which are positive allosteric modulators of one or more GABA-A receptors and which selectively target the peripheral nervous system and organs of the body, and which do not substantially pass through the blood-brain barrier. Said compounds are useful e.g., for the treatment of systemic diseases of the body, e.g., diseases in which modulation of one or more peripherally restricted GABA-A receptors is beneficial (e.g., diseases or disorders which are mediated by GABA-A neuronal activitye. This disclosure also features pharmaceutical compositions containing the chemical entities described herein as well as methods of using same for the treatment of systemic diseases of the body.